Author Index

Ahuja, S. *see* Gupta, R.K., 185
Alexandrova, G.I., Budilovsky, G.N., Koval, T.A., Polezhaev, F.I., Garmashova, L.M., Ghendon, Yu Z., Romanova, Y.R. and Smorodintsev, A.A. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial, 114
Alonson Fernández, A. *see* Augé de Mello, P., 105
Alving, C.R., Richards, R.L., Moss, J., Alving, L.I., Clements, J.D., Shiba, T., Kotani, S., Wirtz, R.A. and Hockmeyer, W.T. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen, 166
Alving, L.I. *see* Alving, C.R., 166
Andre, F.E. *see* Vodopija, I., 233
Arnon, R. *see* Jacob, C.O., 95
Augé de Mello, P., Olascoaga, R.C., Costa Giomi, M.P., Alonson Fernández, A., Scodeller, E.A., La Torre, J.L. and Bergmann, I.E. RNA fingerprinting of South American prototype aphthovirus strains, 105
Azuma, I. *see* Nishimura, K., 151
Azuma, I. *see* Ukei, S., 21

Baklaić, Z. *see* Vodopija, I., 233
Baklaić, Z. *see* Vodopija, I., 245
Bannatyne, R.M., Jackowski, J. and Cheung, R. Cleaning up pertussis vaccine, 91
Barteling, S.J. *see* Broekhuijsen, M.P., 119
Bergmann, I.E. *see* Augé de Mello, P., 105
Berg, U. *see* Kreuter, J., 125
Bernard, K.W. *see* Dreesen, D.W., 45
Bispo de Fillipis, A.M. *see* Schatzmayr, H.G., 111
Blom, T. *see* Broekhuijsen, M.P., 119
Bogaerts, H. *see* Vodopija, I., 233
Brisou, B. *see* Roche, J.C., 163
Broekhuijsen, M.P., Blom, T., Kottenhagen, M., Pouwels, P.H., Meloen, R.H., Barteling, S.J. and Enger-Vaulk, B.E. Synthesis of fusion proteins containing antigenic determinants of foot-and-mouth disease virus, 119
Brotman, B. *see* Neurath, A.R., 35
Brown, J. *see* Dreesen, D.W., 45
Budilovsky, G.N. *see* Alexandrova, G.I., 114
Bull, J.R. *see* Farrah, G.H., 217

Camargo, I.F. *see* Yoshida, C.F.T., 253
Campbell, J.B. *see* Landi, S., 99
Chen, M.H., Zhou, Z., Hartley, C.E., Cowan, M. and Skinner, G.R.B. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model, 249
Cheung, R. *see* Bannatyne, R.M., 91
Chiron, J.P. *see* Perrin, J., 241
Clark, H.F., Offit, P.A., Dolan, K.T., Tezza, A., Gogalin, K., Twist, E.M. and Plotkin, S.A. Response of adult human volunteers to oral administration of bovine and bovine/human reassortant rotaviruses, 25
Clements, J.D. *see* Alving, C.R., 166
Cole, F.E., Jr. *see* Levitt, N.H., 157
Corcoran, T. *see* Oxford, J.S., 9
Costa Giomi, M.P. *see* Augé de Mello, P., 105
Coursaget, P. *see* Perrin, J., 241
Cowan, M. *see* Chen, M.H., 249
Cross, A.S. *see* Cryz, S.J., Jr., 15
Cryz, S.J., Jr., Mortimer, P., Cross, A.S., Fürer, E. and Germanier, R. Safety and immunogenicity of a polyvalent *Klebsiella* capsular polysaccharide vaccine in humans, 15
Cucakovich, N. *see* Landi, S., 99

Dandolos, E. *see* Roumeliotou-Karayannis, A., 93
Delem, A. *see* Vodopija, I., 233
Deutsch, A.J. *see* Dreesen, D.W., 45
Dolan, K.T. *see* Clark, H.F., 25
Dreesen, D.W., Bernard, K.W., Parker, R.A., Deutsch, A.J. and Brown, J. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine, 45
Driscoll, B.F. *see* Levenbook, I.S., 225

Edwards, C.C. *see* Pifer, L.L.W., 257
Edwards, K.M., Snyder, P., Thompson, J.M., Johnson, P.R. and Wright, P.F. *In vitro* production of anti-influenza virus antibody after simultaneous administration of H3N2 and H1N1 cold-adapted vaccines in seronegative children, 50
Ellisberg, B.L. *see* Levenbook, I.S., 225
Ellis, R. *see* Hilleman, M.R., 75
Enger-Vaulk, B.E. *see* Broekhuijsen, M.P., 119
Ewald, T. *see* Pedersen, I.R., 173

Farrah, G.H., Bull, J.R. and Greenaway, P.J. Prospects for the clinical management of human cytomegalovirus infections, 217
Field, H.A. *see* Halsey, N.A., 228
Francis, D.P. *see* Halsey, N.A., 228
Fritzell, B. *see* Roche, J.C., 163
Fujita, M. *see* Schatzmayr, H.G., 111
Fukunaga, T. *see* Yamada, A., 32
Fürer, E. *see* Cryz, S.J., Jr., 15

Garba, S.A. and Terry, R.J. Immunogenicity of oil-based contagious bovine pleuropneumonia vaccine in cattle, 266
Garmashova, L.M. *see* Alexandrova, G.I., 114
Gaspar, A.M.C. *see* Yoshida, C.F.T., 253
Germanier, R. *see* Cryz, S.J., Jr., 15
Ghendon, Yu Z. *see* Alexandrova, G.I., 114
Gibbs, P.H. *see* Meadors, G.F., 179
Gitelman, A.K. *see* Sinyakov, M.S., 3
Gogalin, K. *see* Clark, H.F., 25
Gones, D.F.D.L. *see* Yoshida, C.F.I., 253
Greenaway, P.J. *see* Farrah, G.H., 217
Greenland, S. *see* Strassburg, M.A., 38
Gupta, R.K., Sharma, S.B., Ahuja, S. and Saxena, S.N. Effects of elevated temperatures on the opacity and toxicity of pertussis vaccines manufactured with different inactivating agents, 185

Habel, L.A. *see* Strassburg, M.A., 38
Hall, M.J. and Katrak, K. The quest for a herpes simplex virus vaccine: background and recent developments, 138
Halsey, N.A., Reppert, E.J., Margolis, H.S., Francis, D.P. and Field, H.A. Intradermal hepatitis B vaccination in an abbreviated schedule, 228
Hannoun, C. *see* Roche, J.C., 163
Harari, I. *see* Jacob, C.O., 95
Hart, F. *see* Landi, S., 99
Hartley, C.E. *see* Chen, M.H., 249
Hasty, S.E. *see* Levitt, N.H., 157
Hilleman, M.R. and Ellis, R. Vaccines made from recombinant cells, 75
Hockmeyer, W.T. *see* Alving, C.R., 166

Iida, J. *see* Ukei, S., 21
Imanishi, J. *see* Yamada, A., 32
Ishihara, C. *see* Nishimura, K., 151

Jackowski, J. *see* Bannatyne, R.M., 91
Jacob, C.O., Harari, I., Arnon, R. and Sela, M. Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins, 95

Author Index

Ahuja, S. *see* Gupta, R.K., 185
Alexandrova, G.I., Budilovsky, G.N., Koval, T.A., Polezhaev, F.I., Garmashova, L.M., Ghendon, Yu Z., Romanova, Y.R. and Smorodintsev, A.A. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial, 114
Alonson Fernández, A. *see* Augé de Mello, P., 105
Alving, C.R., Richards, R.L., Moss, J., Alving, L.I., Clements, J.D., Shiba, T., Kotani, S., Wirtz, R.A. and Hockmeyer, W.T. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen, 166
Alving, L.I. *see* Alving, C.R., 166
Andre, F.E. *see* Vodopija, I., 233
Arnon, R. *see* Jacob, C.O., 95
Augé de Mello, P., Olascoaga, R.C., Costa Giomi, M.P., Alonson Fernández, A., Scodeller, E.A., La Torre, J.L. and Bergmann, I.E. RNA fingerprinting of South American prototype aphthovirus strains, 105
Azuma, I. *see* Nishimura, K., 151
Azuma, I. *see* Ukei, S., 21

Baklaić, Z. *see* Vodopija, I., 233
Baklaić, Z. *see* Vodopija, I., 245
Bannatyne, R.M., Jackowski, J. and Cheung, R. Cleaning up pertussis vaccine, 91
Barteling, S.J. *see* Broekhuijsen, M.P., 119
Bergmann, I.E. *see* Augé de Mello, P., 105
Berg, U. *see* Kreuter, J., 125
Bernard, K.W. *see* Dreesen, D.W., 45
Bispo de Fillipis, A.M. *see* Schatzmayr, H.G., 111
Blom, T. *see* Broekhuijsen, M.P., 119
Bogaerts, H. *see* Vodopija, I., 233
Brisou, B. *see* Roche, J.C., 163
Broekhuijsen, M.P., Blom, T., Kottenhagen, M., Pouwels, P.H., Meloen, R.H., Barteling, S.J. and Enger-Vaulk, B.E. Synthesis of fusion proteins containing antigenic determinants of foot-and-mouth disease virus, 119
Brotman, B. *see* Neurath, A.R., 35
Brown, J. *see* Dreesen, D.W., 45
Budilovsky, G.N. *see* Alexandrova, G.I., 114
Bull, J.R. *see* Farrah, G.H., 217

Camargo, I.F. *see* Yoshida, C.F.T., 253
Campbell, J.B. *see* Landi, S., 99
Chen, M.H., Zhou, Z., Hartley, C.E., Cowan, M. and Skinner, G.R.B. Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model, 249
Cheung, R. *see* Bannatyne, R.M., 91
Chiron, J.P. *see* Perrin, J., 241
Clark, H.F., Offit, P.A., Dolan, K.T., Tezza, A., Gogalin, K., Twist, E.M. and Plotkin, S.A. Response of adult human volunteers to oral administration of bovine and bovine/human reassortant rotaviruses, 25
Clements, J.D. *see* Alving, C.R., 166
Cole, F.E., Jr. *see* Levitt, N.H., 157
Corcoran, T. *see* Oxford, J.S., 9
Costa Giomi, M.P. *see* Augé de Mello, P., 105
Coursaget, P. *see* Perrin, J., 241
Cowan, M. *see* Chen, M.H., 249
Cross, A.S. *see* Cryz, S.J., Jr., 15
Cryz, S.J., Jr., Mortimer, P., Cross, A.S., Fürer, E. and Germanier, R. Safety and immunogenicity of a polyvalent *Klebsiella* capsular polysaccharide vaccine in humans, 15
Cucakovich, N. *see* Landi, S., 99

Dandolos, E. *see* Roumeliotou-Karayannis, A., 93
Delem, A. *see* Vodopija, I., 233
Deutsch, A.J. *see* Dreesen, D.W., 45
Dolan, K.T. *see* Clark, H.F., 25
Dreesen, D.W., Bernard, K.W., Parker, R.A., Deutsch, A.J. and Brown, J. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine, 45
Driscoll, B.F. *see* Levenbook, I.S., 225

Edwards, C.C. *see* Pifer, L.L.W., 257
Edwards, K.M., Snyder, P., Thompson, J.M., Johnson, P.R. and Wright, P.F. *In vitro* production of anti-influenza virus antibody after simultaneous administration of H3N2 and H1N1 cold-adapted vaccines in seronegative children, 50
Ellisberg, B.L. *see* Levenbook, I.S., 225
Ellis, R. *see* Hilleman, M.R., 75
Enger-Vaulk, B.E. *see* Broekhuijsen, M.P., 119
Ewald, T. *see* Pedersen, I.R., 173

Farrah, G.H., Bull, J.R. and Greenaway, P.J. Prospects for the clinical management of human cytomegalovirus infections, 217
Field, H.A. *see* Halsey, N.A., 228
Francis, D.P. *see* Halsey, N.A., 228
Fritzell, B. *see* Roche, J.C., 163
Fujita, M. *see* Schatzmayr, H.G., 111
Fukunaga, T. *see* Yamada, A., 32
Fürer, E. *see* Cryz, S.J., Jr., 15

Garba, S.A. and Terry, R.J. Immunogenicity of oil-based contagious bovine pleuropneumonia vaccine in cattle, 266
Garmashova, L.M. *see* Alexandrova, G.I., 114
Gaspar, A.M.C. *see* Yoshida, C.F.T., 253
Germanier, R. *see* Cryz, S.J., Jr., 15
Ghendon, Yu Z. *see* Alexandrova, G.I., 114
Gibbs, P.H. *see* Meadors, G.F., 179
Gitelman, A.K. *see* Sinyakov, M.S., 3
Gogalin, K. *see* Clark, H.F., 25
Gones, D.F.D.L. *see* Yoshida, C.F.I., 253
Greenaway, P.J. *see* Farrah, G.H., 217
Greenland, S. *see* Strassburg, M.A., 38
Gupta, R.K., Sharma, S.B., Ahuja, S. and Saxena, S.N. Effects of elevated temperatures on the opacity and toxicity of pertussis vaccines manufactured with different inactivating agents, 185

Habel, L.A. *see* Strassburg, M.A., 38
Hall, M.J. and Katrak, K. The quest for a herpes simplex virus vaccine: background and recent developments, 138
Halsey, N.A., Reppert, E.J., Margolis, H.S., Francis, D.P. and Field, H.A. Intradermal hepatitis B vaccination in an abbreviated schedule, 228
Hannoun, C. *see* Roche, J.C., 163
Harari, I. *see* Jacob, C.O., 95
Hart, F. *see* Landi, S., 99
Hartley, C.E. *see* Chen, M.H., 249
Hasty, S.E. *see* Levitt, N.H., 157
Hilleman, M.R. and Ellis, R. Vaccines made from recombinant cells, 75
Hockmeyer, W.T. *see* Alving, C.R., 166

Iida, J. *see* Ukei, S., 21
Imanishi, J. *see* Yamada, A., 32
Ishihara, C. *see* Nishimura, K., 151

Jackowski, J. *see* Bannatyne, R.M., 91
Jacob, C.O., Harari, I., Arnon, R. and Sela, M. Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins, 95

Jennings, R. *see* Mukhlis, F.A., 191
Johnson, P.R. *see* Edwards, K.M., 50
Jouan, A. *see* Roche, J.C., 163
Juang, R-F. *see* Yamada, A., 32
Joyner, R.E. *see* Pifer, L.L.W., 257

Katrak, K. *see* Hall, M.J., 138
Kent, S.B.H. *see* Neurath, A.R., 35
Kharitonenkov, I.G. *see* Sinyakov, M.S., 3
Kit, M. *see* Kit, S., 55
Kit, S., Kit, M. and McConnell, S. Intramuscular and intravaginal vaccination of pregnant cows with thymidine kinase-negative, temperature-resistant infectious bovine rhinotracheitis virus (bovine herpes virus 1), 55
Koval, T.A. *see* Alexandrova, G.I., 114
Kotani, S. *see* Alving, C.R., 166
Kottenhagen, M. *see* Broekhuijsen, M.P., 119
Kreuter, J., Berg, U., Liehl, E., Soliva, M. and Speiser, P.P. Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants, 125
Kusumoto, S. *see* Ukei, S., 21

Lafon, M. *see* Vodopija, I., 245
Landi, S., Penney, C.L., Shah, P., Hart, F., Campbell, J.B. and Cucakovich, N. Adjuvanticity of stearyl tyrosine on inactivated poliovirus vaccine, 99
La Torre, J.L. *see* Augé de Mello, P., 105
Levenbook, I.S., Elisberg, B.L. and Driscoll, B.F. Rhesus diploid rabies vaccine (adsorbed), neurological safety in guinea pigs and Lewis rats, 225
Levitt, N.H., Ramsbury, H.H., Hasty, S.E., Repik, P.M., Cole, F.E., Jr. and Lupton, H.W. Development of an attenuated strain of chikungunya virus for use in vaccine production, 157
Lieb, L.E. *see* Strassburg, M.A., 38
Liehl, E. *see* Kreuter, J., 125
Ljubičić, M. *see* Vodopija, I., 245
Lupton, H.W. *see* Levitt, N.H., 157

Macconi, F. *see* Ogunkoya, A.B., 77
Major, D. *see* Oxford, J.S., 9
Mäkelä, P. *see* Väänänen, P., 5
Margolis, H.S. *see* Halsey, N.A., 228
Maurice, Y. *see* Schatzmayr, H.G., 111
McConnell, S. *see* Kit, S., 55
Meadors, G.F., Gibbs, P.H. and Peters, C.J. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials, 179
Meloen, R.H. *see* Broekhuijsen, M.P., 119
Mercandante, L.A.C. *see* Yoshida, C.F.T., 253
Mordhorst, C.H. *see* Pedersen, I.R., 173
Mortimer, P. *see* Cryz, S.J., Jr., 15
Moss, J. *see* Alving, C.R., 166
Mukhlis, F.A., Jennings, R., Stephenson, T.J., Quasim, T. and Potter, C.W. Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment, 191
Murdin, A.D. Synthetic peptide vaccines against foot-and-mouth disease, 210

Nishimura, K., Ishihara, C., Ukei, S., Tokura, S. and Azuma, I. Stimulation of cytokine production in mice using deacetylated chitin, 151
Neurath, A.R., Kent, S.B.H., Parker, K., Prince, A.M., Strick, N., Brotman, B. and Sproul, P. Antibodies to a synthetic peptide from the pre-S 120–145 region of the hepatitis B virus envelope are virus-neutralizing, 35
Newman, R. *see* Oxford, J.S., 9
Ntareme, F. *see* Perrin, J., 241

Offit, P.A. *see* Clark, H.F., 25
Ogunkoya, A.B. and Macconi, F. Emergence of antirabies vaccine of unknown origin for human treatment in Nigeria, 77
Okuno, Y. *see* Yamada, A., 32
Olascoaga, R.C. *see* Augé de Mello, P., 105
Oxford, J.S., Corcoran, T., Newman, R., Major, D. and Schild, G.C. Biochemical and antigenic analysis using monoclonal antibodies of a series of influenza A (H3N2) and (H1N1) virus reassortants, 9
Oxford, J.S. *see* Patterson, S., 79

Papaevangelou, G. *see* Roumeliotou-Karayannis, A., 93
Parker, K. *see* Neurath, A.R., 35
Parker, R.A. *see* Dreesen, D.W., 45
Patterson, S. and Oxford, J.S. Early interactions between animal viruses and the host cell: relevance to viral vaccines, 79
Pedersen, I.R., Mordhorst, C.H., Ewald, T. and von Magnus, H. Long-term antibody response after measles vaccination in an isolated arctic society in Greenland, 173
Penney, C.L. *see* Landi, S., 99
Perrin, J., Coursaget, P., Ntareme, F. and Chiron, J.P. Hepatitis B immunization of newborns according to a two dose protocol, 241
Peters, C.J. *see* Meadors, G.F., 179
Pifer, D.D. *see* Pifer, L.L.W., 257
Pifer, L.L.W., Pifer, D.D., Woods, D.R., Joyner, R.E. and Edwards, C.C. Preliminary studies on the development of a vaccine for *Pneumocystis carinii*. I. Immunologic and biochemical characterization, 257
Plotkin, S.A. Live varicella vaccine: the third act?, 74
Plotkin, S.A. *see* Clark, H.F., 25
Polezhaev, F.I. *see* Alexandrova, G.I., 114
Potter, C.W. *see* Mukhlis, F.A., 191
Pouwels, P.H. *see* Broekhuijsen, M.P., 119
Prince, A.M. *see* Neurath, A.R., 35

Quasim, T. *see* Mukhlis, F.A., 191

Ramsbury, H.H. *see* Levitt, N.H., 157
Repik, P.M. *see* Levitt, N.H., 157
Reppert, E.J. *see* Halsey, N.A., 228
Richards, R.L. *see* Alving, C.R., 166
Richardson, S.C. *see* Roumeliotou-Karayannis, A., 93
Roche, J.C., Jouan, A., Brisou, B., Rodhain, R. Fritzell, B. and Hannoun, C. Comparative clinical study of a new 17D thermostable yellow fever vaccine, 163
Romanova, Y.R. *see* Alexandrova, G.I., 114
Rodhain, R. *see* Roche, J.C., 163
Roumeliotou-Karayannis, A., Dandolos, E., Richardson, S.C., Papaevangelou, G. Immunogenicity of a reduced dose of recombinant hepatitis B vaccine, 93

Saxena, S.N. *see* Gupta, R.K., 185
Schatzmayr, H.G., Maurice, Y., Fujita, M. and Bispo de Fillipis, A.M. Serological evaluation of poliomyelitis oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil, 111
Schatzmayr, H.G. *see* Yoshida, C.F.T., 253
Schild, G.C. *see* Oxford, J.S., 9
Scodeller, E.A. *see* Augé de Mello, P., 105
Sela, M. *see* Jacob, C.O., 95
Shah, P. *see* Landi, S., 99
Sharma, S.B. *see* Gupta, R.K., 185
Sinyakov, M.S., Veselov, S.Yu., Gitelman, A.K. and Kharitonenkov, I.G. ELISA detection of influenza haemagglutinin depends on its molecular environment, 3
Shiba, T. *see* Alving, C.R., 166
Shiba, T. *see* Ukei, S., 21
Skinner, G.R.B. *see* Chen, M.H., 249
Smerdel, S. *see* Vodopija, I., 245
Smorodintsev, A.A. *see* Alexandrova, G.I., 114
Snyder, P. *see* Edwards, K.M., 50
Soliva, M. *see* Kreuter, J., 125
Sorvillo, F.J. *see* Strassburg, M.A., 38
Speiser, P.P. *see* Kreuter, J., 125
Sproul, P. *see* Neurath, A.R., 35
Strassburg, M.A., Greenland, S., Sorvillo, F.J., Lieb, L.E. and Habel, L.A. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports, 38

Stephenson, T.J. *see* Mukhlis, F.A., 191
Strick, N. *see* Neurath, A.R., 35
Sureau, P. *see* Vodopija, I., 245
Svjetličić, M. *see* Vodopija, I., 245

Tadano, M. *see* Yamada, A., 32
Terry, R.J. *see* Garba, S.A., 266
Tezza, A. *see* Clark, H.F., 25
Thompson, J.M. *see* Edwards, K.M., 50
Thornton, D.H. A survey of mycoplasma detection in veterinary vaccines, 237
Tokura, S. *see* Nishimura, K., 151
Twist, E.M. *see* Clark, H.F., 25

Ukei, S., Iida, J., Shiba, T., Kusumoto, S. and Azuma, I. Adjuvant and antitumour activities of synthetic lipid A analogues, 21
Ukei, S. *see* Nishimura, K., 151

Väänänen, P., Mäkelä, P. and Vaheri, A. Effect of low level immunity on response to live rubella virus vaccine, 5
Vaheri, A. *see* Väänänen, P., 5
Veselov, S.Yu. *see* Sinyakov, M.S., 3
Vlatkovic, R. *see* Vodopija, I., 233
Vodopija, I., Baklaić, Z., Vlatkovic, R., Bogaerts, H., Delem, A. and Andre, F.E. Combined vaccination with live oral polio vaccine and the bovine rotavirus Rit 4237 strain, 233
Vodopija, I., Sureau, P., Lafon, M., Baklaić, Z., Ljubičić, M., Svjetličić, M. and Smerdel, S. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule, 245
Von Magnus, H. *see* Pedersen, I.R., 173

Wirtz, R.A. *see* Alving, C.R., 166
Woods, D.R. *see* Pifer, L.L.W., 257
Wright, P.F. *see* Edwards, K.M., 50

Xie Xin. An orally administrable brucellosis vaccine – *Brucella suis* strain 2 vaccine, 212

Yamada, A., Imanishi, J., Juang, R-F., Fukunaga, T., Okuno, Y., Tadano, M., Fukai, K., Baba, K. and Yabuuchi, H. Trial of inactivated Japanese encephalitis vaccine in children with underlying diseases, 32
Yoshida, C.F.T., Camargo, I.F., Mercadante, L.A.C., Gaspar, A.M.C., Gones, D.F.D.L. and Schatzmayr, H.G. Hepatitis B serological patterns of asymptomatic carriers in an endemic region and evaluation of blood plasma as a source of hepatitis B vaccine, 253

Zhou, Z. *see* Chen, M.H., 249

Subject Index

Adjuvant: —— and antitumour activities of synthetic lipid A analogues, 21

Adjuvant: Adjuvanticity of stearyl tyrosine on inactivated poliovirus vaccine, 99

Adjuvant: Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen, 166

Adjuvant: Influence of the particle size on the effect of particulate polymeric ——, 125

Adjuvant: Stimulation of cytokine production in mice using deacetylated chitin, 151

Antibody response: Long-term —— after measles vaccination in an isolated arctic society in Greenland, 173

Antigenic determinants: Synthesis of fusion proteins containing antigenic determinants of foot-and-mouth disease virus, 119

Aphthovirus: RNA fingerprinting of South American prototype aphthovirus strains, 105

Blood plasma HBsAg: Hepatitis B serological patterns of asymptomatic carriers in an endemic region and evaluation of blood plasma as a source of hepatitis B vaccine, 253

Bovine herpes: Intramuscular and intravaginal vaccination of pregnant cows with thymidine kinase-negative temperature-resistant infectious bovine rhinotracheitis (—— virus 1), 55

Bovine rhinotracheitis virus: Intramuscular and intravaginal vaccination of pregnant cows with thymidine kinase-negative temperature-resistant infectious —— (bovine herpes virus 1), 55

Brucella suis: An orally administrable brucellosis vaccine – —— strain 2 vaccine, 212

Brucellosis: An orally administrable —— vaccine – *Brucella suis* strain 2 vaccine, 212

Capsular polysaccharide vaccine: Safety and immunogenicity of a polyvalent *Klebsiella* —— in humans, 15

Carriers: Hepatitis B serological patterns of asymptomatic —— in an endemic region and evaluation of blood plasma as a source of hepatitis B vaccine, 253

Cattle: Immunogenicity of oil-based contagious bovine pleuropneumonia vaccine in cattle, 266

Cattle: Synthetic peptide vaccines against foot-and-mouth disease, 210

Chikungunya virus: Development of an attenuated strain of —— for use in vaccine production, 157

Cervical carcinoma: Efficacy of vaccination with Skinner vaccine towards the prevention of herpes simplex virus induced —— in an experimental mouse model, 249

Children: Combined vaccination with live oral polio vaccine and the bovine rotavirus Rit 4237 strain, 233

Children: Live varicella vaccine: the third act?, 74

Children: Serological evaluation of poliomyelitis oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil, 111

Children: Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in ——: an epidemiological control trial, 114

Chitin: Stimulation of cytokine production in mice using deacetylated chitin, 151

Cholera toxin: Antibodies to —— synthetic peptides on increasing size and their reactivity with related toxins, 95

Cholera toxin: Effectiveness of liposomes as potential carriers of vaccines: applications to —— and human malaria sporozoite antigen, 166

Clone selection: Development of an attenuated strain of chikungunya virus for use in vaccine production, 157

Cold-adapted vaccine: *In vitro* production of anti-influenza virus antibody after simultaneous administration of H3N2 and H1N1 —— in seronegative children, 50

Cross-reactivity: Antibodies to cholera toxin synthetic peptides of increasing size and their reactivity with related toxins, 95

Cytokines: Stimulation of —— production in mice using deacetylated chitin, 151

Cytomegalovirus: Prospects for the clinical management of human infections, 217

Diploid cell vaccine: Immune complex-like disease in 23 persons following a booster dose of rabies human ——, 45

ELISA: —— detection of influenza haemagglutinin depends on its molecular environment, 3

Encephalitis: Trial of inactivated Japanese —— vaccine in children with underlying diseases, 32

Endotoxin: Cleaning up pertussis vaccine, 91

Envelope protein sequence: Antibodies to a synthetic peptide from the preS 120–145 region of the hepatitis B virus envelope are virus-neutralizing, 35

Foot-and-mouth disease: Synthesis of fusion proteins containing antigenic determinants of —— virus, 119

Foot-and-mouth disease: Synthetic peptide vaccines against ——, 210

Glycoprotein: Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment, 191

Haemagglutinin: ELISA detection of influenza —— depends on its molecular environment, 3

Heat stability: Comparative clinical study of a new 17D thermostable yellow fever vaccine, 163

Heat stability: Effects of elevated temperatures on the opacity and toxicity of pertussis vaccines manufactured with different inactivating agents, 185

Hepatitis B: Antibodies to a synthetic peptide from the preS 120–145 region of the hepatitis B virus envelope are virus-neutralizing, 35

Hepatitis B: —— immunization of newborns, according to a two dose protocol, 241

Hepatitis B: —— serological patterns of asymptomatic carriers in an endemic region and evaluation of blood plasma as a source of —— vaccine, 253

Hepatitis B: Immunogenicity of a reduced dose of recombinant —— vaccine, 93

Hepatitis B: Intradermal —— vaccination in an abbreviated schedule, 228

Hepatitis B: Vaccines made from recombinant yeast cells, 75

Herpes simplex: Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment, 191

Herpes simplex: Efficacy of vaccination with Skinner vaccine towards the prevention of —— virus induced cervical carcinoma in an experimental mouse model, 249

Herpes simplex: The quest for a —— virus vaccine: background and recent developments, 138

Human: An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule, 245
Human: Prospects for the clinical management of —— cytomegalovirus infections, 217

Inactivated vaccine: Serological evaluation of poliomyelitis oral and —— in an urban low-income population at Rio de Janeiro, Brazil, 111
Inactivating agents: Effects of elevated temperatures on the opacity and toxicity of pertussis vaccines manufactured with different ——, 185
Influenza A: Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial, 114
Influenza: Biochemical and antigenic analysis using monoclonal antibodies of a series of —— A(H3N2) and (H1N1) virus reassortants, 9
Influenza: ELISA detection of —— haemagglutinin depends on its molecular environment, 3
Influenza: —— in the elderly: report of an outbreak and a review of vaccine effectiveness reports, 38
Influenza vaccine: *In vitro* production of anti-influenza virus antibody after simultaneous administration of H3N2 and H1N1 cold adapted vaccines in seronegative children, 50
Immune complex disease: Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine, 45
Immune response: The quest for a herpes simplex virus vaccine: background and recent developments, 138
Immunity: Effect of low level —— on response to live rubella virus vaccine, 5
Immunogenicity trial: Evaluation of a new Rift Valley fever vaccine: safety and ——, 179
Immunogen: Preliminary studies on the development of a vaccine for *Pneumocystis carinii*. I. Immunological and biochemical characterization, 257
Inactivated vaccine: Immunogenicity of oil-based contagious bovine pleuropneumonia vaccine in cattle, 266
Intradermal: —— hepatitis B vaccination in an abbreviated schedule, 228
Isolated population: Long-term antibody response after measles vaccination in an isolated arctic society in Greenland, 173

Japanese encephalitis vaccine: Trial of inactivated —— in children with underlying diseases, 32

Klebsiella: Safety and immunogenicity of a polyvalent —— capsular polysaccharide vaccine in humans, 15

Leukaemic children: Live varicella vaccine: the third act?, 74
Lipid A analogues: Adjuvant and antitumour activities of synthetic ——, 21
Liposomes: Effectiveness of —— as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen, 166

Malaria sporozoite antigen: Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human ——, 166
Measles vaccination: Long-term antibody response after —— in an isolated arctic society in Greenland, 173
Membrane penetration: Early interactions between animal viruses and the host cell: relevance to viral vaccines, 79
Monoclonal antibodies: Biochemical and antigenic analysis using —— of a series of influenza A (H3N2) and (H1N1) virus reassortants, 9
Mycoplasma: A survey of —— detection in veterinary vaccines, 237

Newborn: Hepatitis B immunization of —— according to a two dose protocol, 241
Nigeria: Emergence of anti-rabies vaccine of unknown origin for human treatment in ——, 77

Oral vaccine: An orally administrable brucellosis vaccine – *Brucella suis* strain 2 vaccine, 212
Oral vaccine: Serological evaluation of poliomyelitis oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil, 111

Particle size: Influence of the —— on the adjuvant effect of particulate polymeric adjuvants, 125
Patent Report: 62, 130, 197, 272
Pertussis: Cleaning up —— vaccine, 91
Pertussis vaccine: Effects of elevated temperatures on the opacity and toxicity of —— manufactured with different inactivating agents, 185
Pleuropneumonia: Immunogenicity of oil-based contagious bovine —— vaccine in cattle, 266
Pneumocystis carinii: Preliminary studies on the development of a vaccine for ——. I. Immunological and biochemical characterization, 257
Polio: Combined vaccination with live oral —— vaccine and the bovine rotavirus Rit 4237 strain, 233
Poliomyelitis: Serological evaluation of —— oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil, 111
Polystyrene particles: Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants, 125
Poliovirus: Adjuvanticity of stearyl tyrosine on inactivated —— vaccine, 99
Poly(methyl methylacrylate) particles: Influence of the particle size on the adjuvant effect of particulate polymeric adjuvants, 125
Polymyxin-Sepharose: Cleaning up pertussis vaccine, 91
Polyvalent vaccine: Safety and immunogenicity of a polyvalent *Klebsiella* capsular polysaccharide vaccine in humans, 15

Rabies: An evaluation of second generation tissue culture —— vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule, 245
Rabies: Emergence of anti- —— vaccine of unknown origin for human treatment in Nigeria, 77
Rabies: Immune complex-like disease —— in 23 persons following a booster dose of —— human diploid cell vaccine, 45
Rabies: Rhesus diploid —— vaccine (adsorbed), neurological safety in guinea pigs and Lewis rats, 225
Radial haemolysis: Effect of low level immunity on response to live rubella virus vaccine, 5
Reassortant: Response of adult human volunteers to oral administration of bovine and bovine/human —— rotaviruses, 25
Reassortants: Biochemical and antigenic analysis using monoclonal antibodies of a series of influenza A(H3N2) and (H1N1) virus ——, 9
Recombinant cells: Vaccines made from recombinant yeast cells, 75
Recombinant DNA: Synthesis of fusion proteins containing antigenic determinants of foot-and-mouth disease virus, 119
Recombinant vaccine: Immunogenicity of a reduced dose of recombinant hepatitis B vaccine, 93
Recombinant vaccine: Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial, 114
Rhesus diploid cells: Rhesus diploid rabies vaccine (adsorbed), neurologi-

cal safety in guinea pigs and Lewis rats, 225
Rift Valley fever: Evaluation of a new —— vaccine: safety and immunogenicity trials, 179
RNA fingerprints: RNA fingerprinting of South American aphthovirus strains, 105
Rotavirus: Combined vaccination with live oral polio vaccine and the bovine —— Rit 4237 strain, 233
Rotavirus: Response of adult human volunteers to oral administration of bovine and bovine/human reassortant rotaviruses, 25
Rubella: Effect of low level immunity on response to live —— virus vaccine, 5

Saccharomyces cerevisiae: Vaccines made from recombinant yeast cells, 75
Safety: Evaluation of a new Rift Valley fever vaccine: —— and immunogenicity trials, 179
Skinner vaccine: Efficacy of vaccination with —— towards the prevention of herpes simplex virus induced cervical carcinoma in an experimental mouse model, 000
South America prototype: RNA fingerprinting of —— aphthovirus strains, 105
Stearyl tyrosine: Adjuvanticity of —— on inactivated poliovirus vaccine, 99
Storage: Effects of elevated temperatures on the opacity and toxicity of pertussis vaccines manufactured with different inactivating agents, 185
Synthetic peptide: Antibodies to a —— from the preS 120–145 region of the hepatitis B virus envelope are virus-neutralizing, 35
Synthetic peptides: Antibodies to cholera toxin —— of increasing size and their reactivity with related toxins, 95
Synthetic peptide: —— vaccines against foot-and-mouth disease, 210

Trial: An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule, 245
Trial: Hepatitis B immunization of newborns according to a two dose protocol, 241
Trial: Immunogenicity of a reduced dose of recombinant hepatitis B vaccine, 93
Trial: Intradermal hepatitis B vaccination in an abbreviated schedule, 228
Trial: Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control ——, 114
Tumour necrotic factor: Adjuvant and antitumour activities of synthetic lipid A analogues, 21

Varicella vaccine: Live ——: the third act?, 74
Veterinary vaccines: A survey of mycoplasma detection in ——, 237
Virus entry: Early interactions between animal viruses and the host cell: relevance to viral vaccines, 79
Viral vaccine: Early interactions between animal viruses and the host cell: relevance to viral vaccines, 79

Yellow fever: Comparative clinical study of a new 17D thermostable —— vaccine, 163

Zwitterionic detergent: Characterization and immunogenicity of HSV-1 antigens obtained following —— treatment, 191